A Family Physician's Guide to Chronic Kidney Disease: Evolving Strategies and Emerging Data

Release Date: October 27, 2021
Expiration Date: October 27, 2022

Activity Overview

This online, on-demand virtual symposium brings together experts in the management of chronic kidney disease (CKD) in patients with type 2 diabetes in the primary-care setting. In this educational program, these experts describe renoprotective strategies that may be employed by the family practice physician. The program concludes with a presentation of cases that illustrate the approaches and treatments most likely to lead to improved patient outcomes.
 

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
 

Target Audience

This online, enduring educational program is directed toward primary care physicians, diabetologists, nephrologists, cardiologists, certified diabetes educators, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with CKD.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe recommended diagnostic practices for CKD in patients with type 2 diabetes
• Identify CKD as a unique disease with high risk of cardiovascular and renal comorbidities
• Evaluate the efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists and other therapies under investigation for treatment of patients with CKD
• Recognize the complex pathophysiology of CKD and emerging approaches to intervene in disease progression

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.
 

Chair

Stephen Brunton, MD, FAAFP
Executive Vice President, Education
Primary Care Education Consortium
Winnsboro, SC

Disclosures: Consultant: Abbott Diabetes Care Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Sanofi Genzyme, Xeris Pharmaceuticals Inc., Boehringer Ingelheim; Speakers’ Bureau: Eli Lilly and Company, Bayer, Novo Nordisk, Sanofi, Boehringer Ingelheim

Faculty

George Bakris, MD
Professor of Medicine
Director, Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

Disclosures: Consultant: Merck & Co., Inc.; Bayer HealthCare Pharmaceuticals Inc.; Vascular Dynamics, Inc.; KBP Biosciences Co., Ltd.; Ionis Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; AstraZeneca; Quantum Genomics; Horizon Therapeutics; Novo Nordisk.

Eden Miller, DO
High Lakes Health Care Sisters
Sisters, OR

Disclosures: Grant/Research Support: Pendulum Therapeutics, Abbott Diabetes Care Inc.; Consultant: Eli Lilly & Company, Novo Nordisk, Boehringer Ingelheim, Abbott Diabetes Care Inc.; Other: ADA II Steering Committee.

Jay H. Shubrook, DO, FACOFP, FAAFP
Professor, Primary Care Department
Director, Clinical Research
Director, Diabetes Services
Touro University California College of Osteopathic Medicine
Vacaville, CA

Disclosures: Consultant: Novo Nordisk, Bayer HealthCare Pharmaceuticals Inc., MannKind Corporation.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.